Emergent BioSolutions Inc. (EBS)
$7.06+3.67%Close
BUYRECOVERY · day 21
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $364M
- Beta
- 2.29
- P/E (TTM)
- -2.02
- Short % float
- 19.08%
- Days to cover
- 8.3
- SI change
- -5.0%
- 1W
- +11.53%
- 1M
- +20.27%
- vs SPY 1W
- +10.37%
- vs SPY 1M
- +17.28%
Industry peers
FMP comparable companies · ranked by market cap
- CMPSSELLCOMPASS Pathways plc$1.5BCRISISQ -3$11.47+4.62%
- RIGLBUYRigel Pharmaceuticals, Inc.$901MBULLQ 9$48.72+0.74%
- CRVSSELLCorvus Pharmaceuticals, Inc.$859MCRISISQ 13$10.21+3.04%
- OLMASELLOlema Pharmaceuticals, Inc.$683MCRISISQ -1$7.82+0.00%
- ESPRBUYEsperion Therapeutics, Inc.$661MBULLQ 1$3.18+0.00%
- AQSTSELLAquestive Therapeutics, Inc.$597MRECOVERYQ -4$4.76+0.42%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on EBS?
- LOPJLB’s latest quantitative signal on Emergent BioSolutions Inc. (EBS) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is EBS in?
- Emergent BioSolutions Inc. (EBS) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Emergent BioSolutions Inc. (EBS) do?
- Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, trav…